- Home
- / TScan Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
TScan Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$4.8
2024-10-29
Market Capitalization
$251.6 M
2024-10-29
Revenue
$10.3 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 10.1M | 13.5M | 21.0M | 2.8M | 10.3M |
| General and administrative expense | 13.8M | 20.4M | 26.4M | 30.3M | 32.0M |
| Operating expense total | 80.2M | 137.6M | 146.1M | ||
| EBIT | (48.6M) | (66.6M) | (93.5M) | (134.8M) | (135.8M) |
| EBIT margin, % | -492.3% | -4787.7% | -1315.4% | ||
| Interest income | 1.6M | 8.0M | 12.1M | 8.8M | |
| Interest expense | 3.8M | 3.7M | |||
| Net Income | (48.6M) | (66.2M) | (89.2M) | (127.5M) | (129.8M) |
| EPS | (2.7) | (1.0) | (1.1) | (1.0) |